Skip to main content
. 2024 Jan 28;27(2):375–386. doi: 10.1007/s10120-023-01455-5

Fig. 2.

Fig. 2

Kaplan–Meier estimates of A overall survival and B progression-free survival in patients receiving rivoceranib as ≥4th-line treatment. BSC = best supportive care. HR = hazard ratio. OS = overall survival. PFS = progression-free survival